Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Carlyle leads $312 million funding round for Japanese unicorn Spiber

Published 09/08/2021, 04:02 AM
Updated 09/08/2021, 04:05 AM
© Reuters. FILE PHOTO: The logo of the Carlyle Group is displayed at the company's office in Tokyo, Japan October 17, 2018. REUTERS/Issei Kato

By Makiko Yamazaki and Yuki Nitta

TOKYO (Reuters) - Global private equity firm Carlyle said on Wednesday it led a $312 million funding round for Japanese biotech company Spiber Inc, joining other global investors in betting on a growing number of late-stage Japanese startup firms.

Carlyle's 10 billion yen ($91 million) stake in Spiber represents the group's first non-buyout, minority investment in an unlisted startup in Japan, where startup funding is soaring.

The round, which also includes investments from fund managers Fidelity and Baillie Gifford, will be made through a combination of the allotment of new shares and a capital infusion at a valuation of about 135 billion yen ($1.22 billion).

Spiber makes plant-based protein polymers through microbial fermentation, which can be spun into animal- and plastic-free fibres for clothing, auto parts and other uses.

The 14-year-old company plans to use the proceeds to build a mass production facility in Iowa and to prepare itself for an initial public offering that it targets in several years, Spiber co-founder Kazuhide Sekiyama told Reuters in an interview.

Fuelled by excess global liquidity, funding raised by Japanese startups exceeded $3 billion in the first six months of the year, a half-year record, according to startup data provider INITIAL.

Some of the biggest funding deals this year involved global investors such as KKR and Sequoia Capital, helping expand the list of promising Japanese startups capable of raising large capital in the private markets.

Japan has less than a dozen unicorns - startups with a valuation in excess of $1 billion - partly because the relaxed listing criteria of the Tokyo bourse's emerging market section allows startups to go public in early stages.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Carlyle, a cornerstone investor in Spiber, plans to allocate about 10% of its $2.5 billion Japan-focused buyout fund to similar funding deals for startups.

"We believe we can help them grow their businesses, through M&As and overseas expansions," to an extent they are large enough to debut on the Tokyo bourse's main board or overseas, Carlyle managing director Yusuke Watanabe said in the same interview.

($1 = 110.2600 yen)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.